The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Considerations in implementing personalized medicine for colorectal cancer
Giulia Martini, MD, PhD, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, emphasizes the importance of genomic analysis in colorectal cancer (CRC) for guiding first-line treatment strategies in the clinic. Molecular profiling of patients enables the development of more personalized therapeutics, which is especially important for those with metastatic disease. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
